TWI368737B - Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway - Google Patents

Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Info

Publication number
TWI368737B
TWI368737B TW098143182A TW98143182A TWI368737B TW I368737 B TWI368737 B TW I368737B TW 098143182 A TW098143182 A TW 098143182A TW 98143182 A TW98143182 A TW 98143182A TW I368737 B TWI368737 B TW I368737B
Authority
TW
Taiwan
Prior art keywords
head
selection
treatment
cancer patients
neck cancer
Prior art date
Application number
TW098143182A
Other languages
English (en)
Chinese (zh)
Other versions
TW201028688A (en
Inventor
Heinrich Roder
Maxim Tsypin
Julia Grigorieva
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Publication of TW201028688A publication Critical patent/TW201028688A/zh
Application granted granted Critical
Publication of TWI368737B publication Critical patent/TWI368737B/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Software Systems (AREA)
  • Computing Systems (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Computation (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
TW098143182A 2009-01-20 2009-12-16 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway TWI368737B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/321,393 US7867775B2 (en) 2006-03-31 2009-01-20 Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

Publications (2)

Publication Number Publication Date
TW201028688A TW201028688A (en) 2010-08-01
TWI368737B true TWI368737B (en) 2012-07-21

Family

ID=41559566

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098143182A TWI368737B (en) 2009-01-20 2009-12-16 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Country Status (11)

Country Link
US (1) US7867775B2 (https=)
EP (1) EP2247954B1 (https=)
JP (1) JP5025802B2 (https=)
KR (1) KR101131309B1 (https=)
AT (1) ATE516503T1 (https=)
AU (1) AU2009338174B2 (https=)
CA (1) CA2718113A1 (https=)
ES (1) ES2368784T3 (https=)
IL (1) IL211943A (https=)
TW (1) TWI368737B (https=)
WO (1) WO2010085235A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
CN102770760A (zh) * 2010-02-24 2012-11-07 佰欧迪塞克斯公司 利用质谱分析选择施用治疗剂的癌症患者
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
AU2013287262A1 (en) 2012-07-05 2015-02-26 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
WO2017011439A1 (en) 2015-07-13 2017-01-19 Biodesix, Inc. Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
WO2018129301A1 (en) 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
WO2019032525A1 (en) 2017-08-07 2019-02-14 Genecentric Therapeutics, Inc. PROCESS FOR SUBTYPING EPIDERMOID CARCINOMA OF HEAD AND NECK
WO2019046585A1 (en) * 2017-08-30 2019-03-07 Genecentric Therapeutics, Inc. ANALYSIS OF GENE EXPRESSION SUB-TYPES OF EPIDERMOID CARCINOMA OF HEAD AND NECK FOR TREATMENT MANAGEMENT
US12094587B2 (en) 2018-03-29 2024-09-17 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
US20230386662A1 (en) * 2020-10-19 2023-11-30 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Rapid and direct identification and determination of urine bacterial susceptibility to antibiotics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101107765B1 (ko) 2002-08-06 2012-01-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암의 검출을 위한 생물 마커의 용도
AU2004248140A1 (en) * 2003-05-30 2004-12-23 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
US20050267689A1 (en) * 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
WO2005010492A2 (en) 2003-07-17 2005-02-03 Yale University Classification of disease states using mass spectrometry data
US20090204334A1 (en) 2004-03-30 2009-08-13 Eastern Virginia Medical School Lung cancer biomarkers
ES2425749T3 (es) * 2004-03-31 2013-10-17 The General Hospital Corporation Método para determinar la respuesta del cáncer a tratamientos dirigidos al receptor del factor de crecimiento epidérmico
US20060029574A1 (en) * 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
WO2007109571A2 (en) 2006-03-17 2007-09-27 Prometheus Laboratories, Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

Also Published As

Publication number Publication date
TW201028688A (en) 2010-08-01
EP2247954A1 (en) 2010-11-10
CA2718113A1 (en) 2010-07-29
US20090171872A1 (en) 2009-07-02
AU2009338174A1 (en) 2010-07-29
AU2009338174B2 (en) 2012-02-02
IL211943A0 (en) 2011-06-30
ES2368784T3 (es) 2011-11-22
IL211943A (en) 2014-01-30
US7867775B2 (en) 2011-01-11
KR20110047171A (ko) 2011-05-06
JP2011513728A (ja) 2011-04-28
WO2010085235A1 (en) 2010-07-29
JP5025802B2 (ja) 2012-09-12
HK1148073A1 (en) 2011-08-26
KR101131309B1 (ko) 2012-04-02
ATE516503T1 (de) 2011-07-15
EP2247954B1 (en) 2011-07-13

Similar Documents

Publication Publication Date Title
TWI368737B (en) Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway
Yewale et al. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
Lv et al. EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2
Fung et al. Emerging drugs to treat squamous cell carcinomas of the head and neck
Nagel et al. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines
IL211944A (en) METHOD OF DECISION If a patient with colorectal cancer (CRC) is likely to benefit from a drug inhibitor receptor factor epidermal monoclonal antibody directed to the EGFR pathway
NZ710636A (en) Heterocyclic compounds and uses thereof
EP2668504A1 (en) Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy
Gainor et al. The new kid on the block: RET in lung cancer
Ding et al. Ring finger protein 180 suppresses cell proliferation and energy metabolism of non-small cell lung cancer through downregulating C-myc
Midde et al. Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment
Yu et al. Cbl-b regulates the sensitivity of cetuximab through ubiquitin-proteasome system in human gastric cancer cells
Zhu et al. GRAIL inhibits the growth, migration and invasion of lung adenocarcinoma cells by modulating STAT3/C-MYC signaling pathways
Chaurasiya et al. Virtual screening for identification of novel potent EGFR inhibitors through AutoDock Vina molecular modeling software
Muallaoglu et al. Lack of prognostic significance of C-erbB-2 expression in low-and high-grade astrocytomas
Kim et al. ISU104, a fully human antibody targeting a specific epitope on the ErbB3, displays potent inhibition of tumor growth in multiple xenograft tumor models
莉芬趙 et al. Human Epidermal Growth Factor Receptor and Targeted Therapy for Breast Cancer
Shukla et al. KRAS Mutations in Cancer: Molecular Insights, Therapeutic Advances, and Strategies to Overcome Resistance
Nguyen et al. 508 Different neoantigen expression patterns impact the strength of anti-tumor immune responses
Marcoe et al. Abstract P6-14-17: In Vitro Evaluation of the Anti-EGFR Antibody Cetuximab and the Anti-HER2 Antibody Trastuzumab in a Panel of Human Tumor Cell Lines
Lui et al. Abstract# 4197: Mitogenic dependency of Nasopharyngeal Cancer (NPC) cells on c-Met pathway over EGFR pathway
Darbonne et al. Pharmacodynamic response in a phase 1 clinical study of the potent Hedgehog pathway antagonist GDC-0449 using a GLI1 qRT-PCR assay
Fox et al. Abstract S3-8: RNAi Screening Identifies the Insulin/Insulin-Like Growth Factor-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Estrogen Receptor-Positive Breast Cancer
Cheng et al. EGFR-mediated interleukin enhancer-binding factor 3 contributes to formation and survival of cancer stem-like tumorspheres through regulating HER3/ERBB3 expression as a therapeutic target against EGFR-positive non-small cell lung cancer
Zhang et al. Synthesis and Biological Activity of Multi-targeting Platinum (Ⅱ) Anticancer Complexes

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees